Curie.Bio
Xin Huang is an accomplished professional in structural biology and protein sciences, currently serving as Senior Vice President at Curie.Bio since October 2024. Previously, Xin held the role of Senior Vice President of Early Discovery at Nested Therapeutics from March 2023 to September 2024, where leadership encompassed structural biology, biophysics, and biochemistry. At Kymera Therapeutics, from February 2021 to March 2023, Xin advanced from Executive Director to Vice President, contributing significantly to targeted protein degradation programs. Earlier experience includes a Senior Director position at IFM Therapeutics and various leadership roles at Amgen, culminating in a Scientific Director role, overseeing strategic initiatives in drug discovery and structural biology. Xin's educational background includes multiple degrees from Columbia University, as well as postdoctoral training at Harvard Medical School/Dana Farber Cancer Institute and the University of North Carolina at Chapel Hill.
This person is not in any teams
Curie.Bio
2 followers
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.